The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
32 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $80,873,466 in first-year total cost, median $2,470,716.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-T (M1)]8
- Special Emphasis Panel[ZCA1 RPRB-M (J1)]4
- Special Emphasis Panel[ZCA1 RPRB-T (J1)]4
- Special Emphasis Panel[ZCA1 RPRB-H (J1)]2
- Special Emphasis Panel[ZCA1 RPRB-H (O1)]2
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR3
- DANA-FARBER CANCER INST2
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Fusion oncoprotein condensates in pediatric cancers1P01CA298963-01 | KRIWACKI, RICHARD WMULLIGHAN, CHARLES G | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $3,032,826 | ZCA1 |
| 2025 | Immunobiology and Immune Therapy for Merkel Cell Carcinoma2P01CA225517-06A1 | NGHIEM, PAUL | UNIVERSITY OF WASHINGTON, WA | $2,994,993 | ZCA1 |
| 2025 | Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma2P01CA049605-34A1 | MIKLOS, DAVID B.NEGRIN, ROBERT S | STANFORD UNIVERSITY, CA | $2,936,016 | ZCA1 |
| 2025 | Advancing Hormone Therapy for Endometrial Cancer1P01CA278735-01A1 | GERTZ, JASONLESLIE, KIMBERLY K. | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $2,801,881 | ZCA1 |
| 2025 | Mutant p53 in Tumorigenesis, Invasion, and Metastasis1P01CA291694-01A1 | MANFREDI, JAMES J | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $2,679,816 | ZCA1 |
| 2025 | Ceramide-Directed Therapeutics for Treatment of AML1P01CA302570-01 | CHALFANT, CHARLES E.LOUGHRAN, THOMAS P. | UNIVERSITY OF VIRGINIA, VA | $2,663,053 | ZCA1 |
| 2025 | The Molecular Drivers and Therapeutic Susceptibilities in Lineage State Transitions of Metastatic Prostate Cancer1P01CA298991-01 | LANG, JOSHUA | UNIVERSITY OF WISCONSIN-MADISON, WI | $2,579,971 | ZCA1 |
| 2025 | Lipid Metabolism as a Determinant of Ferroptosis Sensitivity in Cancer1P01CA291697-01A1 | JIANG, XUEJUN | SLOAN-KETTERING INST CAN RESEARCH, NY | $2,489,032 | ZCA1 |
| 2025 | Convergent Epigenetic Control of Neuroendocrine Cancers1P01CA295524-01 | DECAPRIO, JAMES A. | DANA-FARBER CANCER INST, MA | $2,452,400 | ZCA1 |
| 2025 | Polymerase theta, genome instability, and cancer2P01CA247773-06 | RAMSDEN, DALE A | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $2,440,899 | ZCA1 |
| 2025 | InHANCE: Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery1P01CA278716-01A1 | BROCK, KRISTYFULLER, CLIFTON DAVIDHUTCHESON, KATHERINE ARNOLDLAI, STEPHEN Y | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,392,505 | ZCA1 |
| 2025 | The impact of changes in chromatin architecture on cancer phenotypes and tumor progression2P01CA229086-06A1 | SKOK, JANE AMANDA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $2,304,725 | ZCA1 |
| 2025 | Sphingolipids in Cancer Biology and Therapy2P01CA097132-21A1 | HANNUN, YUSUF AWNI | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $2,208,375 | ZCA1 |
| 2025 | Tipping Points in Cancer1P01CA288662-01A1 | LANDER, ARTHUR DLAWSON, DEVON A.LOWENGRUB, JOHN | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $2,186,372 | ZCA1 |
| 2025 | Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy.1P01CA296429-01A1 | CZERNIAK, BOGDAN AMCCONKEY, DAVID J. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,108,734 | ZCA1 |
| 2025 | Development of Novel Therapeutic Strategies in Human Leukemias2P01CA066996-26 | ARMSTRONG, SCOTT AEBERT, BENJAMIN LEVINE | DANA-FARBER CANCER INST, MA | $2,052,164 | ZCA1 |
| 2025 | APOBEC Mutagenesis in Cancer2P01CA234228-06A1 | HARRIS, REUBEN SYEE, DOUGLAS | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $2,002,938 | ZCA1 |
| 2025 | Androgen Receptor Action in Castration Resistant Prostate Cancer2P01CA163227-11A1 | BALK, STEVEN P. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,990,456 | ZCA1 |
| 2025 | Retrovirus Models of Cancer2P01CA100730-21 | RATNER, LEE | WASHINGTON UNIVERSITY, MO | $1,971,061 | ZCA1 |
| 2025 | Discovery of Anticancer Agents of Diverse Natural Origin2P01CA125066-16 | FUCHS, JAMES RKINGHORN, ALAN DOUGLASOBERLIES, NICHOLAS H. | OHIO STATE UNIVERSITY, OH | $1,640,056 | ZCA1 |
| 2024 | Adult Leukemia Research Center2P01CA018029-48A1 | HILL, GEOFFREY ROGER | FRED HUTCHINSON CANCER CENTER, WA | $4,359,202 | ZCA1 |
| 2024 | WISDOM: A platform to optimize subtype-specific screening and prevention1P01CA281826-01A1 | ESSERMAN, LAURA JVAN'T VEER, LAURA J | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $3,537,456 | ZCA1 |
| 2024 | Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment2P01CA163222-11 | FISHER, DAVID E | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,800,993 | ZCA1 |
| 2024 | Aging-related hematopoietic stem cell intrinsic and microenvironmental signals in AML transformation1P01CA285250-01A1 | KOUSTENI, STAVROULA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $2,775,137 | ZCA1 |
| 2024 | ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE)1P01CA275740-01A1 | SARKAR, DEVANAND | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $2,678,459 | ZCA1 |
| 2024 | Imaging and Genomic Signatures of Brain Tumor Heterogeneity and Evolution to Optimize Patient Management2P01CA118816-16 | CHANG, SUSAN MLUPO, JANINE MARIEVIGNERON, DANIEL B | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $2,654,906 | ZCA1 |
| 2024 | Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche1P01CA272295-01A1 | CERCHIETTI, LEANDRO CFLOWERS, CHRISTOPHER R | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $2,561,215 | ZCA1 |
| 2024 | Regulation of BRCA-dependent Genome Repair via the 53BP1 Axis1P01CA275717-01A1 | SUNG, PATRICK | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $2,556,071 | ZCA1 |
| 2024 | OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVIVORship1P01CA285249-01A1 | FULLER, CLIFTON DAVIDHUTCHESON, KATHERINE ARNOLDLAI, STEPHEN Y | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,447,812 | ZCA1 |
| 2024 | Role of hypernutrition and metabolic stress in non-alcoholic steatohepatitis (NASH) driven hepatocellular carcinoma (HCC)1P01CA281819-01A1 | KAUFMAN, RANDAL J. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $2,397,277 | ZCA1 |
| 2024 | Understanding Integration in Oncology Care and Association with Quality and Outcomes1P01CA281850-01A1 | KEATING, NANCY LLANDRUM, MARY BETH | HARVARD MEDICAL SCHOOL, MA | $2,282,687 | ZCA1 |
| 2024 | Investigating and Targeting Replication Stress in Small Cell Lung Cancer1P01CA288368-01 | HUANG, TONY TUNGPOIRIER, JOHN THOMAS | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $1,893,978 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.